Irish Sunday Post / Lars interview

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Irish Sunday Post / Lars interview

Postby better2gether » Sun Mar 06, 2005 3:18 am

Irish Sunday Post / Lars interview

Tysabri: The inside story

06 March 2005

On February 17, Elan and its partner, Biogen, announced promising results from a two-year trial on their multiple sclerosis (MS) drug, Tysabri.

Within days, they learned of a fatality and a second case of viral symptoms from patients using a combination of Tysabri and Biogen's Avonex drug.

Lars Ekman, head of research and development of Elan, talks about the countdown to the suspension of Tysabri by the Food and Drug Administration.

Lars Ekman: There was one confirmed case of the disease, progressive multifocal leukoencephalopathy (PML), induced by a virus that appeared in one of our patients.

Eamon Quinn: When did that come to your attention?

LE: It came to our attention after we announced the [results of] two-year data.
The information came to Elan via Biogen. These adverse advents are handled by Biogen. They have a specific process, and in the end, they inform us, and that came to our attention after the release of our two-year data.

EQ: How big was that study?

LE: Out of a total of 3,000 patients who had been treated.
So, that is one case out of 3,000 patients [in North America].
There was one patient who was confirmed and then there was another one who is suspected. But we are not yet able to get any confirmation on that patient because, in all honesty, they are not able to find the virus or the right pathologies.
We do not know what that other case is. But we have one case.

EQ: Where is that case?

LE: We do not [disclose that] for confidentiality reasons . . . it is somewhere in the western United States.

[The second case of PML was confirmed after the interview]

EQ: Were all 3,000 on the combo Tysabri and Avonex?

LE: Out of 3,000 of the total patient population that has been on Tysabri, there is 558 who have been on this combo therapy. They have been on the combo therapy for two years or more, between two and four years.

EQ: This didn't appear before November, before the FDA approved Tysabri?

LE: Oh no. You have to remember we had data on one year with very strong efficacy [showing] outstanding results and safety features. The two-year data also showed strong safety features.
It is important that you remember that every therapy has some severe adverse advent. That you do have some adverse advents is an integrated part of an effective therapy.
In Europe and the US, we have many thousands of patients with MS who have today failed current treatments. And those patients will either die or be crippled by their disease.
So what we are trying to do together with the FDA is two things. We are trying to identify the prevalence, so we can tell the medical community how frequent this is, what the risk is.
The second is how can you diagnose it and how can you treat it, because if you have an adverse advent, you want to know what to look out for.
Because you can then focus on whether this is a severe case of MS or whether it is this PML situation. And if you find an adverse advent how can you treat it.

EQ: What happened after February 17?

LE: We immediately forwarded the information to the FDA, and it entered into the FDA system. We contacted the FDA with both a written and a verbal communication. And in the week that followed, we together with the FDA tried to gather more information about the patient.
We discussed various actions. I have been 25 years in the industry and I have never experienced a situation where you stop distributing a drug for one patient.

EQ: Were you shocked by the decision?

LE: Last week [to Monday, February 28],we had a number of conversations with the FDA, and I think that the political environment and the sensitivity to the management of adverse advents have changed drastically in the US at this point.
I think that the FDA had a desire to act promptly. We and the FDA, said: “Let's take the most conservative action we can think of.” We decided to stop dosing the patients in the trial, and temporarily to suspend dosing the patients.

EQ: With combo or altogether?

LE: We discussed firstly only to do it with combo.
But we jointly decided, we said let's pause and then investigate all patients so we know exactly what we are talking about.

EQ: And that decision was taken when?

LE: That decision was taken at the end of last week. I do not want to go into the details.
We met both face-to-face and in various phone calls with the FDA many times last week. We jointly decided that it was the right action to take and that was then immediately executed.

EQ: You stopped the trial over the weekend, did you?

LE: Yes. That is correct. We thought to take the most ethical action we can, because we are so convinced that this drug has exceptional value for MS patients (and) Crohn's patients and also we as a company wanted to take the high road. Let's take the most ethical action we can in order to learn more.
It was also clear in the conversation with the FDA that this was a matter of months.
Once we have the material we will jointly review it and decide when we will bring the drug back to the market.
Bringing it back to the market would also [involve] bringing the information that we have learned in this investigation. Then, we will be able to write on the packages that the prevalence of this phenomenon is such and such, and this is how you should diagnose it.
We would then have done everything possible to help the MS patients.

EQ: Were you surprised [following announcement of the two-year trial on February 17] when you heard these results?

LE: I was personally informed two and half days after the announcement. Our safety people got the signal about 36 hours after the announcement. I was personally informed on the Sunday after the announcement of the two-year data.

EQ: Sunday February 20?

LE: That is correct. We do not have the record when this information came to Biogen.
We can only say when this information was forwarded into the Elan system.
There is a defined operating procedure. You cannot just pass on information. You have to go through a number of steps. You have to validate the information. On February 17, we announced our two-year data. I was personally informed on February 20.

EQ: How can it happen that a combo (therapy) has a reaction?

LE: In the one confirmed case, you cannot say with 100 per cent certainty that it is combo alone. We think that it is related to combo, but we don't know that.
If you have two immune modulators in combination, you may get an effect that you can't predict using one drug by itself.
So, we do not know at all whether there is a causality between the drug and this side-effect. All of these questions need to be addressed.

EQ: And the other case?

LE: The other case was a patient of a similar age in their mid-40s.The patient was on the dose for over two years and documented itself in symptoms that suggested that it could be PML.
Then an investigation started doing all the necessary tests on the brain and the cerebral spinal fluids.

EQ: The communication after February 17 up to last Monday. Is that a normal time period?

LE: I think it is exceptionally fast. I think from the time when companies notify when they have done their investigations and when they have been to the FDA, in many cases, the turnaround time from notification to action was about ten days. It is exceptionally fast.
Normally, you would have to have a much longer period to investigate what is really happening. It is a difficult trade-off, because you have to think of all those patients who are benefiting from the drug.
MS is a disease which can lead to disability and death. It is not an easy decision. This is not a pain drug. This is a drug that prevents a severely-disabling disease.

EQ: Can those 3,000 be put on another drug?

LE: It is too early to say how they are treated. They may be put on Tysabri when it is reintroduced. We will talk to the FDA about when it can be reintroduced. There will be a number of interactions with the FDA in how we are going to manage these patients.

EQ: What happens now? Is the second case key to this process?

LE: No. Even if we have a third case, it is not key. What is key is to go back into all the information we have. We have these brain scans on the patients. Those scans will be reanalysed.
We will also be taking new scans on all the patients and we will be doing a clinical work-up on each patient.
When all of that is done ,we will have a good understanding whether there is another patient or whether this is a single case.
Together with the FDA, we will then be able to say how can we inform the patients, how can we inform the physicians and when is the appropriate time to bring the drug back to the patients.
We, as well as the FDA, have a desire to do so. The FDA on its website took the unusual step of claiming that this was a very important drug for the MS patient. It was eager to resolve this as fast as possible.
I want to point out that the FDA has not suspended our licence to market it. The FDA has not taken any legal action. We still have our licence. This is by no means a legal action by the FDA.

EQ: Is it like the Alzheimer's setback of a few years before?

LE: No, it is not. That was a very, very different situation. This is a drug which has been tested in patients for five years altogether. It has gone through thousands of patients.
These are the biggest MS and Crohn's trials done ever in the history of medicine.
They have all revealed exceptional results and have a strong safety record.

EQ: Obviously, the FDA is not going to do something rash?

LE: What Kelly Martin [chief executive of Elan] told the market is that our goal is to bring the drug back in the third quarter. That remains our goal.

EQ: If the 3,000 test is suspended, talk me through what you need to do to satisfy that everything is safe by the third quarter?

LE: The process is that we are having meetings with various experts on this [PML] disease. We are conducting a programme with the FDA which includes a new medical assessment of all the patients - all the 3,000 patients who have been treated with Tysabri.

EQ: Will Tysabri for use in Crohn's and rheumatoid arthritis be delayed? You were to do a big trial on one for rheumatoid arthritis this year?

LE: For Crohn's, we have done the last study. We are currently analysing whether we can close that study and if so, we will have all the data, and the Crohn's indication would not be affected at this point.
We have already filed in Europe. The Europeans have all the information they want and need.
Assuming we can close that trial - we are doing the bio-statistical analysis as we speak - the Crohn's trial should be on track.
This specific trial has about 500 patients. In total, we will have more than 1,200 patients on the Crohn's drug across Europe and the US.
We have previously said that we would aim to file, if the data supports the filing, by mid-year. If we can close the trial, we would be able to stick to that timeline.

EQ: And with rheumatoid arthritis, you were planning a robust trial?

LE:The Phase II study is being analysed right now. I do not have the details myself. I assume we will have some delays.
I do not know whether it is three months or six months.
But I do not think that the basic facts have changed.

EQ: What are your feelings on the combo? Are the problems caused by the combo [of Tysabri with Avonex]?

LE: I think it would be unprofessional to speculate on this one case.

We do not have the data to support that one way or another. ... qqqx=1.asp
Last edited by better2gether on Sun Mar 06, 2005 5:21 am, edited 1 time in total.
User avatar
Family Elder
Posts: 188
Joined: Sun Dec 19, 2004 4:00 pm


Irish Sunday Independent / Elan

Postby better2gether » Sun Mar 06, 2005 3:52 am

Irish Sunday Independent / Elan

06 March 2005


A SERIOUS rift has divided Elan and the US Food and Drugs Administration (FDA) over the suspension of the drug which caused the collapse in Elan's share price last week. Fierce accusations are being made that the company acted too hastily. It is emerging this weekend that the shock decision to suspend the drug was taken by Elan and its partner Biogen without the agreement of the FDA.

Yesterday, sources at the FDA were keen to distance themselves from Elan's decision. A spokesman for the authority said that they "were made aware of the decision".

When pressed he insisted that "it was made by the company" and refused to comment when asked if they supported the suspension.

A spokeswoman for Elan claimed that it was a decision agreed not only by Elan and its partner Biogen, but also by the FDA. She claimed that "all three were in favour of the suspension of the drug [Tysabri] from marketing".

When challenged with the FDA's statement, that they were merely "made aware of the decision", she insisted that Elan and Biogen had "consulted" with the authority and that they were in "close conversation" with it.

News of the reluctance of the FDA to back up Elan's suspension of the drug will add to growing criticism of the firm's precipitate action which caused the shares to plunge by 78 per cent last week.

Those to suffer in the market bloodbath included all the directors. On Wednesday an excoriating editorial on Elan's behaviour ran in the Wall Street Journal. It called the withdrawal of the drug "an overreaction that will harm MS patients in the near term and all of us who depend on a healthy drug-development culture over the long run".

Instead of targeting the regulator (the FDA) it thundered on: "the natural hyper-caution of regulators is exceeded only by the hyper-caution of terrified drug makers".

Adding to speculation that Elan only pulled the marketing of the drug for fear of legal cases it condemned the "climate of fear" created by trial lawyers and "CEOs who imagine they're doing patients and shareholders a favour with such rash decisions".

Shareholders in Elan were certainly done no favours last week. Brokers were reluctant to speculate on the market reaction had the drug not been suspended and an alternative action, approved by the FDA, taken. One source suggested "carnage in the market could have been avoided if precedent was followed and a 'Dear Doctor' letter had been sent out to all those prescribing the drug to warn them of the dangers associated with the current events."

Elsewhere there was speculation that Elan and partner Biogen had been in sharp disagreement about the decision to suspend the drug.

Brokers noted that the two partners had, unusually, held separate conference calls to explain their decision, fuelling rumours that the two parties were not united.

One broker said that it was unlikely that Biogen would have been pushing hard for suspension as it would have been aware that several directors had given due notice of sales of their Biogen shares for a date just before the announcement was made.

They would have been aware that the media was bound to focus on the timing of the share sales and to point out the vast amounts made by Biogen directors by selling prior to the collapse.

The media duly obliged but Biogen sources defended the criticism by suggesting that the directors could hardly anticipate that two patients on the drug would suffer terminal illnesses on the dates of the sales. ... ssue_id=12 182
User avatar
Family Elder
Posts: 188
Joined: Sun Dec 19, 2004 4:00 pm

Postby OddDuck » Sun Mar 06, 2005 5:31 am

MS is a disease which can lead to disability and death.

Well, there's the confirmation that even the companies don't fully understand MS. And right from one of the horse's mouths. That's reassuring. Nobody can argue with this, right?

Now comes all the finger pointing, apparently.

If they were giving this drug to people for almost 5 years, then I still would like ONE reporter to ask them about their OWN research findings that I posted earlier wherein they THEMSELVES found and published some obviously known potential problems, but they didn't tell anybody.

Perhaps that is someone's "ace in the hole", though, and is just waiting until Elan or Biogen or the FDA or all THREE hang themselves and then they will spring it on them. Possibly in court? Who knows?


EDIT: Now that makes me wonder what the media "polling" the MS patients was really all about.
User avatar
Contributing Author
Posts: 1040
Joined: Sat Jun 19, 2004 3:00 pm
Location: Tennessee

Postby PhireX » Sun Mar 06, 2005 6:32 pm

OddDuck, correct me if I'm wrong- I'm one of the people who basically says that MS does not cause death- however, arent there certain cases where the patient can lose control over functions like automatic breathing, etc and in about 1% of cases, MS is the cause of death?

Hate to be a downer :)
User avatar
Family Member
Posts: 54
Joined: Wed Jan 19, 2005 4:00 pm

Postby OddDuck » Sun Mar 06, 2005 6:39 pm

That's really rare.

No, I've never known, read or heard of MS to cause complete loss of control over automatic breathing at all. That is ALS, not MS.

If death is said to be "caused" from MS, it's really from some sort of secondary condition or complication, not from MS itself.

Maybe others will disagree, but that's not what I have found in my research.

User avatar
Contributing Author
Posts: 1040
Joined: Sat Jun 19, 2004 3:00 pm
Location: Tennessee

Postby PhireX » Sun Mar 06, 2005 6:47 pm

I suppose it depends where you read your info from. I know you know your stuff, and was going to mention the 10% of people that supposedly die from secondary symptoms- but that isnt the MS still.

Glad I dont have ALS....I had a friend who hooked me up with a doctor to get my LDN in my local area, and he said he had "Laterel Sclerosis", and I looked it up and found ALS. Fortunately for him, he has PLS, not ALS.

Anyway this is going off topic now :)
User avatar
Family Member
Posts: 54
Joined: Wed Jan 19, 2005 4:00 pm

Postby OddDuck » Sun Mar 06, 2005 7:25 pm

Yeah, no problem.

True........(re: where certain information comes from). I know it wasn't long ago that there was thought that MS may "cause" death in a small percentage of cases, but............well, I still believe it is very rare.

Nothing is impossible, that's for sure. But all in all, I think the majority can rest assured that fatality is not the norm by any means.

(PLS is not fun, either, I understand. I went through that "possible PLS or ALS" diagnosis for a bit there myself. Now THERE is a frightening experience, I can tell ya! Please give your friend my best!)

And the same to you!

All the best, :)

User avatar
Contributing Author
Posts: 1040
Joined: Sat Jun 19, 2004 3:00 pm
Location: Tennessee

Postby DenverCO » Sun Mar 06, 2005 8:45 pm


Very informative articles. Hopefully a re-evaluation of the data can be expedited quickly and Tysabri will be back on the market by the 3rd quarter.
User avatar
Family Elder
Posts: 119
Joined: Wed Nov 24, 2004 4:00 pm

Postby Arron » Mon Mar 07, 2005 12:36 am

great articles... thx for posting.
Disclaimer: Any information you find on this site should not be considered medical advice. All decisions should be made with the consent of your doctor, otherwise you are at your own risk.
User avatar
Volunteer Moderator
Posts: 893
Joined: Sun Feb 01, 2004 4:00 pm
Location: California, USA

Return to Tysabri (Antegren or Natalizumab)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service